ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Plasma Biomarkers for Alzheimer's Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies.Cellular and molecular neurobiology · 2026Pooled it
- Neuroinflammatory fluid biomarkers in patients with Alzheimer's disease: a systematic literature review.Molecular psychiatry · 2025Pooled it
- Effects on cognition of regional astrogliosis assessed byResearch square · 2026Article
- Characterization of Clinical Phenotype to Glial Fibrillary Acidic Protein Concentrations in Alexander Disease.Annals of clinical and translational neurology · 2026Article
- Blood ATX(N) Biomarkers and Cognitive Dysfunction in Severe Mental Illnesses.International journal of molecular sciences · 2026Review
- Independent and interactive contributions of white matter hyperintensities and Alzheimer's disease imaging and plasma biomarkers to cognitive decline in older adults without dementia.Alzheimer's research & therapy · 2026Article
- Sleep quality as a modifier of plasma phosphorylated tau 217 and glial fibrillary acidic protein associations with cognitive function.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Postmortem Associations Between Alzheimer Disease Pathology and Plasma pTau217, GFAP, and NfL in AD and AD-Related Dementias.Neurology · 2026Article
- Plasma p-tau217 and glucose metabolism correlate in neocortical association areas in Alzheimer's disease.Brain communications · 2026Article
- Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Article
- Exploring nightly variability and clinical influences on sleep measures: insights from a digital brain health platform.Sleep medicine · 2025Article
- Glial reactivity correlates with synaptic dysfunction across aging and Alzheimer's disease.Nature communications · 2025Article
- Circulating short chain fatty acids in Alzheimer's disease: A cross-sectional observational study.Journal of Alzheimer's disease : JAD · 2025Observational
- Sex differences on tau, astrocytic, and neurodegenerative plasma biomarkers.Journal of Alzheimer's disease : JAD · 2025Article
- Beat-to-beat blood pressure variability, hippocampal atrophy, and memory impairment in older adults.GeroScience · 2025Article
- Blood-Based Biomarkers and Risk of Onset of Mild Cognitive Impairment Over the Short and Long Term.Neurology · 2025Observational
- The exploration of using plasma biomarkers of p-tau217 and p-tau181 for screening Alzheimer's disease in very elderly people.Frontiers in neurology · 2025Article
- Emerging biomarkers of postoperative delirium at the intersection of neuroinflammation and neurodegeneration.Frontiers in aging neuroscience · 2025Review
- Plasma vesicle-associated membrane protein 2 and glial fibrillary acidic protein associate with synaptic density in older adults without dementia.Brain communications · 2025Article
- Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer's disease.Acta neuropathologica · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 4 institutions in 5 countries.
Funding
Abstract
Introduction: This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p-tau) Methods: Plasma samples were analyzed using Simoa platform for 567 participants spanning the AD continuum. Cognitive diagnosis, neuropsychological testing, and dementia severity were examined for cross-sectional and longitudinal outcomes. Results: Plasma GFAP discriminated AD dementia from normal cognition (adjusted mean difference = 0.90 standard deviation [SD]) and mild cognitive impairment (adjusted mean difference = 0.72 SD), and demonstrated superior discrimination compared to alternative plasma biomarkers. Higher GFAP was associated with worse dementia severity and worse performance on 11 of 12 neuropsychological tests. Longitudinally, GFAP predicted decline in memory, but did not predict conversion to mild cognitive impairment or dementia. Discussion: Plasma GFAP was associated with clinical outcomes related to suspected AD and could be of assistance in a plasma biomarker panel to detect in vivo AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.